Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

February 28, 2026

Study Completion Date

May 31, 2026

Conditions
Scleroderma, DiffuseScleroderma, SystemicScleroderma, LimitedSclerosis, Progressive SystemicSkin DiseasesConnective Tissue DiseasesPathologic ProcessesAutoimmune Diseases
Interventions
DRUG

Oral Ifetroban

Subjects will be treated with oral ifetroban or placebo daily for 365 days

DRUG

Oral Placebo

Subjects will be treated with oral ifetroban or placebo daily for 365 days

Trial Locations (13)

10021

Hospital for Special Surgery, New York

19107

Thomas Jefferson University, Philadelphia

21224

Johns Hopkins University, Baltimore

29403

Medical University of South Carolina, Charleston

33331

Cleveland Clinic - Florida, Weston

68198

University of Nebraska Medical Center, Omaha

85724

The Universtity of Arizona Arthrtis Center, Tucson

160012

PGIMER, Chandigarh

400053

KDH - Kokilaben Dhirubhai Ambani Hospital, Mumbai

411001

B. J. Government Medical College, Pune

90095-1670

UCLA, Los Angeles

02114

Massachusetts General Hospital, Boston

75204-651

Baylor Research Institute, Dallas

Sponsors
All Listed Sponsors
lead

Cumberland Pharmaceuticals

INDUSTRY